Skip to content

French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study

French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management: the FRENCH CORONA Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04340466
Acronym
FRENCH CORONA
Enrollment
1003
Registered
2020-04-09
Start date
2020-04-03
Completion date
2020-07-03
Last updated
2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona Virus Infection, Critically Ill, Pneumonia, Viral

Keywords

COVID-19, SARS-Cov-2, Intensive Care Unit

Brief summary

Since December 2019, a new agent, the SARS-Cov-2 coronavirus has been rapidly spreading from China to other countries causing an international outbreak of respiratory illnesses named COVID-19. In France, the first cases have been reported at the end of January with more than 60000 cases reported since then. A significant proportion (20-30%) of hospitalized COVID-19 patients will be admitted to intensive care unit. However, few data are available for this special population in France. We conduct a large observational cohort of ICU suspected or proven COVID-19 patients that will enable to describe the initial management of COVID 19 patients admitted to ICU and to identify factors correlated to clinical outcome.

Interventions

OTHERNo intervention

No intervention

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients admitted to ICU for suspected or proven SARS-Cov-2 infection, defined by positive SARS-Cov-2 PCR or CT scan images * Patient \> or= 18 years

Exclusion criteria

* Patient study refusal * Patient already enrolled in the present study * Patient with respiratory illness with negative COVID-19 CT scan images and negative COVID\_19 PCR

Design outcomes

Primary

MeasureTime frameDescription
Mortality at day 28day 28Mortality at day 28

Secondary

MeasureTime frameDescription
Imagingday 1Delay in imaging in hours
Delay in Microbiological diagnosisday 1delay in microbiological diagnosis in hours
Antiviral therapyup to day 28Antiviral therapy Yes / no
Antibiotic therapyday 28Antibiotic therapy Yes / No
severe complicationsup to day 28severe complications (pulmonary embolism, acute kidney injury, myocarditis, cardiac arrest, liver failure, ventilator associated pneumonia) Yes / No
Patients receiving renal replacement therapyup to day 28number
Patients receiving mechanical ventilationup to day 28number
Vital statusday 28Patient alive at day 28 : yes / No
Covid-19 treatmentsup to day 28Covid-19 treatments Yes / No

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026